反应详情

To a solution of 3-(2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester (4.54 g, 10.02 mmol) in THF (100 mL) was added NaH (481 mg, 12.02 mmol, 60% dispersion in mineral oil) and the mixture allowed to stir for 5 min before the addition of iodomethane (750 μL, 12.02 mmol) and 15-Crown-5 (10 drops). The resulting mixture was allowed to stir for 2.5 h then concentrated in vacuo. The resulting residue was partitioned between EtOAc and H2O and the aqueous layer further extracted with 2-methyl THF. The combined organic phases were dried (Na2SO4) and concentrated in vacuo affording 3-(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-3-methoxypiperidine-1-carboxylic acid tert-butyl ester (4.30 g, 92%). LCMS (method A): RT 4.05 min, [M+H]+ 467.2

1. concentrationthen concentrated in vacuo
2. customThe resulting residue was partitioned between EtOAc and H2O
3. extractionthe aqueous layer further extracted with 2-methyl THF
4. dry with materialThe combined organic phases were dried (Na2SO4)
5. concentrationconcentrated in vacuo